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Patrick Peeters7, Frank Vermassen8, and Mario Landini9 on behalf of the IN.PACT DEEP Trial InvestigatorsAbstract
Background: The effectiveness and durability of endovascular revascularization therapies for chronic critical limb
ischemia (CLI) are challenged by the extensive burden of infrapopliteal arterial disease and lesion-related characteristics
(e.g., severe calcification, chronic total occlusions), which frequently result in poor clinical outcomes. While infrapopliteal
vessel patency directly affects pain relief and wound healing, sustained patency and extravascular care both contribute to
the ultimate “patient-centric” outcomes of functional limb preservation, mobility and quality of life (QoL).
Methods/Design: IN.PACT DEEP is a 2:1 randomized controlled trial designed to assess the efficacy and safety of
infrapopliteal arterial revascularization between the IN.PACT Amphirion™ paclitaxel drug-eluting balloon (IA-DEB) and
standard balloon angioplasty (PTA) in patients with Rutherford Class 4-5-6 CLI.
Discussion: This multicenter trial has enrolled 358 patients at 13 European centers with independent angiographic core
lab adjudication of the primary efficacy endpoint of target lesion late luminal loss (LLL) and clinically driven target lesion
revascularization (TLR) in major amputation-free surviving patients through 12-months. An independent wound core lab
will evaluate all ischemic wounds to assess the extent of healing and time to healing at 1, 6, and 12 months. A QoL
questionnaire including a pain scale will assess changes from baseline scores through 12 months. A Clinical Events
Committee and Data Safety Monitoring Board will adjudicate the composite primary safety endpoints of all-cause death,
major amputation, and clinically driven TLR at 6 months and other trial endpoints and supervise patient safety throughout
the study. All patients will be followed for 5 years. A literature review is presented of the current status of endovascular
treatment of CLI with drug-eluting balloon and standard PTA. The rationale and design of the IN.PACT DEEP Trial are
discussed. IN.PACT DEEP is a milestone, prospective, randomized, robust, independent core lab-adjudicated CLI trial that
will evaluate the role of a new infrapopliteal revascularization technology, the IA-DEB, compared to PTA. It will assess the
overall impact on infrapopliteal artery patency, limb salvage, wound healing, pain control, QoL, and patient mobility. The
1-year results of the adjudicated co-primary and secondary endpoints will be available in 2014.
Trial registration: NCT00941733
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Percutaneous transluminal angioplasty (PTA) is an estab-
lished alternative to open surgical bypass for the treatment
of infrainginual disease of critical limb ischemia (CLI) pa-
tients with limited life expectancy, multiple surgical comor-
bidities, and/or those who lack an adequate venous conduit
[1-3]. Several studies established lower peri-procedural
mortality and morbidity and high technical success for
PTA, leading some centers to consider infrapopliteal artery
angioplasty, particularly in specific high-risk CLI patient co-
horts, to be the “first line” therapeutic approach [4-7]. Con-
versely, the extent and burden of infrapopliteal arterial
disease, particularly in diabetics, are well described [8], and
high post-PTA restenosis rates have been consistently re-
ported [9-11]. Nonetheless, reports that include adjudica-
tion of restenosis rates by an independent angiographic
core lab as part of a large multicenter randomized con-
trolled trial are lacking. Likewise, the impact of high infra-
popliteal vessel restenosis rates on the prognosis of CLI
patients is unclear. Yet, despite concerns of high infrapopli-
teal PTA restenosis rates, the limb salvage rates appear ac-
ceptable [10] when compared to open lower limb bypass
[12]. Thus, there is an evolving impression, endorsed by so-
cietal guidelines [13,14], that the potential near-term benefit
of the less invasive PTA approach in CLI patients, when
compared to surgery, favors PTA as the “first line ap-
proach” in specific patients. The potential negative impact
on limb salvage of a required percutaneous reintervention
or surgical bypass after a failed PTA remains, however, a
concern. Recent data suggest that patients who experienced
tibial PTA restenosis and who subsequently underwent a
lower limb bypass required more distal target anastomoses
[15] and had higher 1-year amputation and graft closure
rates [16] when compared to patients without prior PTA.
Likewise, the BASIL trial investigators observed that pa-
tients undergoing bypass after a failed PTA had worse
amputation-free survival (AFS) rates than those undergoing
primary bypass [3]. Therefore, there is an evolving concern
that CLI patients followed for a longer time period will
demonstrate high tibial PTA restenosis rates that may ul-
timately require lower extremity bypass, which are, in turn,
associated with higher bypass failure rates and worse out-
comes [16].
Paclitaxel drug-eluting balloons are designed to pro-
mote arterial patency by reducing neointimal prolifera-
tion. In prospective clinical trials in relatively small CLI
patient cohorts, tibial vessel drug-eluting balloon (DEB)
angioplasty was associated with significantly reduced re-
stenosis rates and late lumen loss (LLL) at 3, 6, and
12 months [17-19]. Although these angiographic assess-
ments were not core lab adjudicated, there is a growing
perception that the clinical results of DEB tibial angio-
plasty mirror the clinical experience in the superficial
femoral artery in claudicants [20-23]. However, thepotential for tibial artery DEB angioplasty to provide a
more durable patency rate and, thereby, potentially fa-
vorably impact limb salvage, wound healing, time to
wound healing, pain control, quality of life (QoL) indi-
ces, and mobility has yet to be defined in a prospective,
robust, randomized assessment compared to PTA.
IN.PACT DEEP was initiated as the first trial to system-
ically assess the Safety and Efficacy of the new IN.PACT
Amphirion™ paclitaxel drug-eluting balloon (IA-DEB)
technology in CLI patients with infrapopliteal disease.
Hypothesis
We hypothesize that the IA-DEB will significantly re-
duce angiographically assessed target lesion late lumen
loss (LLL) compared to standard PTA in infrapopliteal
lesions up to 10 cm in length and reduce clin-
ically driven target lesion revascularization (TLR) in
amputation-free surviving CLI patients through 12
months. Moreover, we assumed that the IA-DEB would
be non-inferior to PTA with reference to the rate of all-
cause death, major amputation, and clinically driven
TLR through 6 months.
Methods/Design
Trial design
This trial is a 2:1 randomized, controlled, patient-blinded
multicenter trial that compares the IA-DEB to PTA in
terms of angiographically assessed target lesion LLL and
clinically driven TLR of infrapopliteal arteries in Rutherford
class 4-5-6 symptomatic critical limb ischemia patients
through 12 months (Figure 1). Consecutive patients match-
ing all General Eligibility Criteria (Table 1 Sections A-D)
were consented for the trial. All patients were required to
be free of further general procedural exclusion criteria
(Table 1 Section E) such as unsuccessful crossing of the tar-
get lesion with a guide wire.
This trial is composed of two subject cohorts (Clinical co-
hort and Angio cohort), the second characterized by more
restrictive eligibility criteria than the first: subjects who met
certain additional and specific eligibility criteria and avoided
specific exclusion criteria (Table 1 Sections F and G) were
allocated to an “Angio” cohort; the others were allocated to
the “Clinical” cohort. Finally, subjects were randomized 2:1
to IA-DEB or PTA within their assigned cohort. All sub-
jects from both cohorts will be part of the clinical assess-
ment and followed for 5 years post-randomization. Only
subjects from the Angio cohort will undergo angiographic
evaluation at 12 months. In August 2012, the IN.PACT
DEEP Trial completed enrollment of 358 subjects
(Figure 1).
Primary efficacy endpoints
The IN.PACT DEEP trial was designed before there was
preliminary evidence of the degree of efficacy of DEB
Figure 1 IN.PACT DEEP treatment cohort assignment/randomization flowchart.
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therefore decided to choose a method capable of distin-
guishing even subtle differences in performance. LLL as-
sessment is considered the most sensitive, objective
determinant of post-intervention vessel narrowing; this
methodology was accordingly selected as the best arbiter
of a potential DEB treatment effect. Thus, an angio-
graphic core lab-adjudicated infrapopliteal artery target
lesion LLL at 12 months post-intervention (applying to
the Angio cohort only) and clinically driven TLR
through 12 months (applying to the entire subject popu-
lation) were selected as co-primary endpoints to provide
assessment of vessel patency in the two treatment co-
horts from both angiographic and clinical perspectives.
“Clinically driven” TLR is defined as (1) directed by an
increase in size of a pre-existing wound(s) and/or (2) oc-
currence of a new wound(s), and/or (3) deterioration in
Rutherford class. To assist in quantitation of wound
healing assessments, all investigational sites were pro-
vided with and trained on the use an electronic wound
reader able to objectively record the morphological sta-
tus of wound’s area and depth (SilhouetteMobile™, Aranz
Medical Ltd., Auckland, New Zealand). An independent
Wound Core Lab. (SynvaCor, Springfield, IL) subse-
quently adjudicated data. USA. Important “patient-cen-
tric” secondary endpoints to be assessed include time to
wound healing, change in ischemic pain, quality of life
(QoL), and walking capacity. Other secondary endpoints
include amputation-free survival (AFS), major adverseevents (MAE) and sustained clinical improvement. The
primary safety endpoint is described below; secondary
endpoints and major inclusion/exclusion clinical and
angiographic criteria are detailed in Tables 1 and 2,
respectively.
Subjects
A total of 358 patients with symptomatic Rutherford
class 4-5-6 CLI who matched the trial eligibility criteria
were randomized 2:1 to treatment with IA-DEB (N =
239) or PTA (N = 119). One hundred sixty-seven of
these subjects were allocated to the Angio cohort (113
subsequently randomized to IA-DEB and 54 to PTA)
and the remaining 191 to the Clinical cohort (126 subse-
quently randomized to IA-DEB and 65 to PTA). LLL
angiography will be assessed at the 12-month follow-up
for the Angio cohort only and clinically driven TLR
through 12 months will be assessed in all subjects. All
subjects will be evaluated yearly for 5 years.
Eligibility criteria
Subjects were required to meet all general, angiographic
and procedural eligibility criteria (Table 1A-E; see below)
to be considered for the trial. If any of the exclusion cri-
teria (Table 1B and E) were met, the subject was ex-
cluded from the trial.
Subjects who met certain specific additional inclusion
and exclusion criteria (see Figure 1 and Table 1F and G)
were allocated to the Angio cohort. A maximum lesion
Table 1 IN.PACT DEEP inclusion and exclusion criteria
(A) General inclusion criteria
i.1 Age ≥ 18 years and ≤85 years
i.2 Patient or patient’s legal representative has been informed of the
nature of the study, agrees to participate, and has signed an EC-
approved consent form
i.3 Female patients of childbearing potential have a negative
pregnancy test ≤7 days before the procedure and are willing to use
a reliable method of birth control for the duration of study
participation
i.4 Patient has documented chronic critical limb ischemia (CLI) in the
target limb prior to the study procedure with Rutherford category 4,
5, or 6
i.5 Life expectancy >1 year in the investigator’s opinion
(B) General exclusion criteria
e.1 Patient unwilling or unlikely to comply with follow-up schedule
e.2 Planned major index limb amputation
(C) General angiographic inclusion criteria
i.6 Reference vessel diameter(s) between 2 and 4 mm
i.7 Single or multiple lesions with ≥70% DS of different lengths in
one or more main afferent crural vessels including tibioperoneal
trunk
i.8 At least one non-occluded crural vessel with angiographically
documented run-off to the foot either directly or through collaterals
(D) General angiographic exclusion criteria
e.3 Lesion and/or occlusions located in or extending to the popliteal
artery or below the ankle joint space
e.4 Inflow lesion or occlusion in the ipsilateral iliac, SFA, or popliteal
arteries with length ≥15 cm
e.5 Significant (≥50% DS) inflow lesion or occlusion in the ipsilateral
iliac, SFA, or popliteal arteries left untreated
e.6 Previously implanted stent in the TL(s)
e.7 Aneurysm in the target vessel
e.8 Acute thrombus in the TL
(E) General procedural exclusion criteria
e.9 Failure to obtain <30% residual stenosis in pre-existing,
hemodynamically significant (≥50% DS and <15 cm length) inflow
lesions in the ipsilateral iliac, SFA, or popliteal artery. DES and/or DEB
was not allowed for the treatment of inflow lesions
e.10 Failure to cross the TL with a 0.014′ guide wire
e.11 Use of alternative therapy, e.g., atherectomy, cutting balloon,
laser, radiation therapy, DES as part of the index procedure
(F) Angiographic cohort angiographic inclusion criteria
a.i.1 Angio-TL is one identifiable single solitary or a series of multiple
adjacent lesions with a DS≥ 70% and a cumulative length≤ 100 mm
that can be covered by a single IN.PACT Amphiron™ (10-mm balloon
landing zone in both edges is mandatory)
a.i.2 Angio-TL is the only lesion in that vessel (only 1 Angio-TL per
patient is allowed)
(G) Angiographic cohort general exclusion criteria
a.e.1 GFR <30 ml/min except for patients with renal end-stage disease
on chronic hemodialysis
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the technical assessment of LLL by the blinded core lab.
Extent of infrapopliteal revascularization and wound
healing
The angiosome concept, introduced by Taylor et al. [24],
is an anatomic unit of tissue, fascia, muscle, and bone
fed by a source artery and drained by specific veins. The
lower extremity and foot are divided into six spe-
cific angiosomes fed by the posterior tibial artery
(3 angiosomes), anterior tibial artery (1 angiosome), and
peroneal artery (2 angiosomes). Alterations in regional
pedal circulation impact successful healing in patients
with ischemic ulcers [25,26]. Regional perfusion differ-
ences may be accentuated if the source or wound-
related artery (WRA) to the ischemic angiosome is
occluded and collateral vessels perfuse the impacted
angiosome indirectly.
Various contributing factors that influence successful
revascularization and impact wound healing have been
described. Iida [25] and Neville [27] demonstrated sig-
nificantly improved wound healing and rates of freedom
from amputation when direct pulsatile flow via the
WRA was established compared to when indirect revas-
cularization was implemented. Peregrin [28] observed
that better outcomes were achieved with revasculariza-
tion of a greater number of vessels, while Faglia [29] re-
ported that perfusion via the anterior and/or posterior
tibial arteries generally resulted in better outcomes when
compared to peroneal artery recanalization alone. Still
better outcomes were achieved with revascularization of
a greater number of vessels. Additionally, the import-
ance of foot vascular anatomy [30], pedal circulation
[31], and micro-circulation [32] to CLI outcomes has
been recently emphasized. Ultimately, the revasculariza-
tion target and extent of the infrapopliteal/pedal revas-
cularization remain an area of great interest and debate
in CLI treatment. To address these issues, the IN.PACT
DEEP trial will evaluate the impact of direct vs. indirect
revascularization and the number of revascularized
vessels on wound healing and limb salvage. This pro-
spective evaluation consented subjects prior to the
confirmation of full eligibility, which included some
angiographic and procedural criteria. Subjects who failed
angiographic and procedural eligibility criteria were con-
sidered “screen failures”. The screen failures were not
considered as enrolled subjects for the purposes of
intent-to-treat (ITT) analysis.
Randomization
Randomization of subjects proceeded after all procedural
and angiographic eligibility criteria had been met,
including the requirements that all inflow lesions had
been successfully treated and that the guidewire had
Table 2 IN.PACT DEEP trial secondary endpoints
(1) Amputation-free survival at 30 days, 3 and 6 months, 1, 2, 3, 4 and 5 years
(2) Rate of wound healing at 30 days, 6 months, 1 and 2 years
(3) Amputation-free survival and wound healing at 6 months, 1 and 2 years
(4) Amputation-free survival and resolved CLI at 6 months, 1 and 2 years
(5) Death, amputation, and clinically driven TLR at 30 days, 6 months, 1 and 2 years
(6) Primary sustained clinical improvement: an improvement shift in the Rutherford classification of 1 class in amputation-free, clinically driven TLR-
free surviving patients at 1 year
(7) Secondary sustained clinical improvement: an improvement shift in the Rutherford classification of 1 class including the need for clinically
driven TLR in amputation-free surviving patients at 1 year
(8) QoL assessment by EQ5D at 6 months, 1 and 2 years vs. baseline
(9) Walking capacity assessment by WIQ at 6 months, 1 and 2 years
MAE at 30 days, 6 months, 1, 2, 3, 4, and 5 years
(10) Device success defined as the exact deployment of the device according to the instructions for use as documented with suitable imaging
modalities and, in the case of digital subtraction angiography, in at least two different imaging projections
(11) Technical success defined as successful vascular access and completion of the endovascular procedure and immediate morphological success
with ≤50% residual diameter reduction of the treated lesion on completion angiography
(12) Procedural success defined as combination of technical success, device success and absence of procedural complications
(13) For the Angio cohort: improvement in 12 months of percent diameter stenosis (%DS) of the TL assessed by quantitative vascular angiography
(14) Days of hospitalization
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into the distal true lumen (Table 1). The randomization
process was performed using blocks of sealed envelopes.
Ethics
This trial is conducted in accordance with the principles
of the Declaration of Helsinki, ISO 14155 and Good
Clinical Practices guidelines. The Ethics Committees of
all investigational sites (Table 3) approved the trial
protocol, and written informed consent was obtained
from all subjects before enrollment. Subjects and theirTable 3 Ethics committees used in the IN.PACT DEEP trial
Site name Ethics comm
Park-Krankenhaus Leipzig-Südost GmbH/Herzzentrum Leipzig
GmbH
Ethik Kommis
University of Bern Angiology Division Nationale Eth
Medical Care Center Prof. Mathey, Prof. Schofer GmbH
FEKI (Prof H.P.
Freiburg
University of Heidelberg
Herz-Zentrum Bad Krozingen Angiology
A.Z. Sint-Blasius Vascular Surgery
Universitair Zi
9000 Ghent
Imelda Hospital Cardiovascular & Thoracic Surgery
Ghent University Hospital Vascular Surgery
Zol St-Jan Commissie M
Medical University Graz Ethikkommiss
Villa Maria Eleonora Hospital Comitato Bioe
Luzerner Kantonsspital Präsident der
Lucerne 16
St. Antonius Hospital VCMO ST Anttreating physicians retained the right to withdraw
from the trial and all follow-ups at any time without
prejudice.
Safety and quality control
Data safety monitoring board
A Clinical Events Committee (CEC) will assess the
composite primary safety endpoints of all-cause death,
major amputation, and clinically driven TLR through
12 months and will adjudicate other trial endpoints. A
Data Safety Monitoring Board (DSMB) will periodicallyittees
sion, Härtelstrasse 16–18, 04107 Leipzig
ikkommission Bern, Generalsekretärin, Postfach 56, CH-3010 Bern
Graf MD, PhD) Nationale Ethikkommission, Mozartstrasse 21, DE-79104
ekenhuis Gent, Commissie voor Medische Ethiek, De Pintelaan 185B, BE
edische Ethiek, Schiepse Bos 6, BE-3600 Genk
ion, Univ.Prof. DI Dr. Haas, Aenbruggerplatz 2, A-8036 Graz
tico, Aziendale, Via G. Cusmano n.24, 90141 Palermo
Ethik Kommission des Kantons Luzern, Luzerner Kantonspital, 6000
oniusziekenhuis, Koekoekslaan 1, 3435 CM Nieuwegein
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and progress.
Adverse and serious adverse events
Adverse events (AEs) are defined as any untoward med-
ical occurrence in a subject whether or not considered
related to the study device that is identified or worsens
during the trial. AEs are classified following the flow-
chart below (Figure 2).
AEs will be assessed and documented by the site investi-
gators at the time of the procedure and at all follow-up
visits (scheduled and unscheduled). All suspected AEs will
be recorded on the AE Log in the electronic clinical report
form (e-CRF). An adverse device effect (ADE) is any unto-
ward and unintended response to a medical device includ-
ing any event resulting from insufficiencies or inadequacies
in the instructions for use or the deployment of the device
as well as any event that is a result of a user error.
AEs will be classified on the AE Log of the e-CRF as
follows, with categories 3 to 5 considered to meet the defin-
ition of a serious adverse event (SAE): (1) no therapy, no
consequence; (2) nominal therapy, no consequence; (3)
required intervention to prevent serious outcome; (4)Untoward medical occ
MAE
(defined per 
Procedure-
related?
Meets criteria
AE
S
Device-
related?
ADE AE procedure-
related
 AE
no
no
yes yes
no no
Figure 2 Adverse events categorization flowchart.hospitalization or prolongation of hospitalization; (5) per-
sistent/significant disability/incapacity life-threatening/
death. Major or minor wound debridement is not consid-
ered an AE. SAEs include AEs of categories 3–5 and in-
clude any untoward medical occurrence in a subject which:
1. Led to a death or
2. led to a serious deterioration in the health of the
subject that:urence
?
protoco
 for SA
ADE
Ua. resulted in a life-threatening illness or injury, and/or
b. resulted in a permanent impairment of a body
structure or body function, and/or
c. required subject hospitalization or prolongation
of existing hospitalization and/or
d. resulted in a medical or surgical intervention to
prevent permanent impairment to body structure
or body function.A serious adverse device effect (SADE) is an adverse ef-
fect that results in any of the consequences characteristic of
an SAE or that might have led to any of these consequences
had suitable action not been taken, had intervention not
been made, or had circumstances been less opportune. in a subject
l)
E?
Report as MAE; 
continue with further definition
SAE
Procedure-
related?
Device-
related?
UADE
nanticipated?
SAE procedure-
related
SAE
yes
yes
yes yes
no no
no yes
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as (1) any serious adverse effect on health or safety or any
life-threatening problem or death caused by or associated
with the use of the investigational device if that effect, prob-
lem, or death was not previously identified in nature, sever-
ity, or degree of incidence in the investigational plan or
application (including a supplementary plan or application)
or (2) as any other unanticipated serious problem associ-
ated with a device that relates to the rights, safety, or wel-
fare of subjects.
In addition to the “generic” AE Log, dedicated sections
are present in the e-CRF allowing tracking of specific
events as follows: (1) all TLR; (2) all target extremity re-
vascularization (TER); (3) all deaths; (4) all amputations;
(5) all UADEs.
MAEs as in Figure 2 are defined as composite
rates of all-cause death, minor amputation, and major
amputation.
Statistical analysis
The total sample size for the IN.PACT DEEP trial was cal-
culated at 357 subjects, which fully powers the primary co-
efficacy endpoint of LLL (80%) and the primary composite
safety endpoint (80%) based on initial estimates of event
rates and effect sizes of the two arms, IA-DEB and PTA,
randomized 2:1. The primary co-efficacy endpoint of 12-
month TLR is powered to 65% with the indicated sample
size.
Primary co-efficacy endpoints
The first primary efficacy endpoint is LLL, assessed at
12 months or at the time of TLR; the second is
incidence of clinically driven TLR assessed through
12 months. Each will be tested for superiority in a com-
parison of the randomized groups.
Sample size consideration
Primary efficacy endpoint: angiographic cohort
The statistical hypothesis of superiority is assessed using
a two-sample t-test of IA-DEB versus PTA, with 5%
two-sided alpha and 80% desired power. Estimates rele-
vant to the LLL primary efficacy endpoint depend on
two observations:
1. The hypothesized treatment effect – that is, the
mean difference between the IA-DEB and PTA arms
at 12 months.
2. An estimate of variability, specifically the standard
deviation (SD).
To obtain estimates of these numbers, a meta-analysis of
PTA by Romiti et al. [12] was examined for results on (bin-
ary) primary patency. The indicated value was 58.1% at
12 months, meaning that 58.1% of enrolled subjects in thestudies summarized had binary primary patency (restenosis
less than 50%) at 12 months. The value of 58.1% for binary
patency was used in a simulation to estimate the mean LLL
indexed to reference vessel diameter as follows.
1. The standard deviation of indexed LLL was assumed
to be 0.25, which is a reasonably conservative value
for a random variable of this type.
2. Indexed LLLs were then simulated as being drawn
from a normal distribution such that 58.1% of the
cumulative distribution function lay below 0.5, the
value that defines binary patency. Based upon the
parameters above, the mean for the PTA group is
estimated to be 0.45. This is reasonable in that it is
somewhat less than 0.5, which would be expected to
be the case since more than half of subjects had
binary patency.
Assuming a 30% relative reduction in mean indexed
LLL in the IA-DEB group compared to the PTA
group—that is, a mean in the IA-DEB group of (1–0.3)
(0.45) = 0.315—and accounting for 25% potential end-
point attrition (larger than the 10% for safety since death
is not included in the endpoint and the period of follow-
up is longer), the resulting sample size is 168 (with 112
expected in the IA-DEB group and 56 in the PTA group)
subjects in the randomized subgroup qualifying for
evaluation of LLL. Note: subjects undergoing bailout or
provisional stenting in either randomized arm are con-
sidered to continue as normal for endpoint analysis (per
ITT principles as below).
Primary efficacy endpoint: clinical cohort
For the efficacy endpoint of 12-month TLR, the statistical
hypothesis is tested using Fisher’s exact test of proportions
of IA-DEB versus PTA, again with 5% two-sided alpha and
80% desired power. For this endpoint, it is assumed that
among evaluable subjects (that is, those not lost to follow-
up), 50% of PTA subjects will undergo TLR during the 12-
month follow-up and that a relative reduction of 30% in
TLR will be seen in IA-DEB subjects, resulting in a rate of
[(1–0.3) (0.5) = 0.35] 35% for TLR in IA-DEB subjects. After
25% attrition as before, the required sample size is 504.
As this sample size is larger than the intended enroll-
ment for the trial, the power for this endpoint in the
current trail based upon intended sample size of 357 is
65% rather than 80%. An interim analysis will be con-
ducted when 150 subjects have attained 12 months of
follow-up for the purpose of potentially stopping early
for efficacy on this endpoint.
Primary safety endpoint
The primary safety endpoint for the proposed trial is a
composite of all-cause death, major amputation, and
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Blackwelder’s [33] method between the randomized
groups and evaluated at the 6-month follow-up visit with
a non-inferiority margin defined at 10%. For this end-
point, it is assumed that among evaluable subjects (that
is, those not lost to follow-up), 40% of PTA subjects will
experience an event meeting the safety endpoint by the
6-month follow-up and that a relative reduction of 15%
in TLR will be seen in IA-DEB subjects, resulting in a
rate of [(1–0.15) (0.4) = 0.34] 34% in IA-DEB subjects.
After 10% potential attrition relative to this endpoint,
the required sample size is 357 (with 238 expected in
the IA-DEB group and 119 in the PTA group). The
power for this test is greater than 80%.
Early trial termination
An interim analysis of 150 subjects at 12 months to as-
sess the primary safety and efficacy endpoints is to be
performed by an independent group and maintained
confidentially. The objective of this interim analysis is
two-fold:
 To permit early stopping of the trial for
overwhelming efficacy (and not futility)
 For use in designing and powering a subsequent
United Stated Investigational Device Exemption (US
IDE) trial.
The interim analysis to assess all of the primary safety
and efficacy endpoints will be conducted once 150 sub-
jects (approximately 100 IA-DEB and 50 PTA) have
reached their 12-month follow-up visits. This interim
look would permit early stopping for efficacy using an
O’Brien-Fleming-type alpha-spending function. Based on
150 out of 357 total enrolled subjects in the trial, the
two-sided P-values required at the interim and final
looks will be 0.006 and 0.048, respectively.
Incorporating the Hochberg adjustments, efficacy would
be met at the interim look if at least one of the co-primary
endpoints is met at a P-value of 0.003 or if both are met at
0.006; similarly, at the final look, efficacy will be met if ei-
ther of the co-primary endpoints is met at a P-value of
0.024 or if both are met at 0.048.
Intervention
Before the initiation of the interventional procedure, a 55-
cm radiopaque ruler was affixed to the index extremity ex-
tending from tibial tuberosity to the level of the lateral
malleolus. This approach ensured adequate angiographic
documentation of the tibial lesion treatment zone and as-
sured appropriate angiographic analysis (i.e., LLL) within
the treatment zone on all subsequent planned imaging
studies and unplanned interventions. Approach to the tib-
ial artery target lesion was contralateral retrograde oripsilateral antegrade. Accessing the target lesion (TL) from
the popliteal or pedal approach was contraindicated. All
imaging was to be performed using digital subtraction angi-
ography. If the subject met the pre-specified angiographic
cohort eligibility criteria (Table 1), the subject was select-
ively entered into the angiographic cohort trial arm.
The treatment objective is to obtain a patent infrapo-
pliteal artery target lesion, with uninterrupted blood flow
to the foot. Therefore, significant lesions in the aorto-
iliac and/or femoropopliteal arterial segments were
treated during the index procedure. However, treatment
success of the inflow lesion was to be documented as
successful (i.e., residual stenosis <30% by visual esti-
mate). This interventional strategy conforms to standard
of practice in maximizing inflow into the infrapopliteal
segment in CLI patients.
Prior to intervention, digital subtraction angiography
of the inflow segment and pedal runoff imaging were re-
quired. Standard interventional techniques in crossing
arterial stenoses and/or occlusions were to be employed;
re-entry devices in the infrapopliteal segment were con-
traindicated. Pre-dilatation with an undersized (non-
drug-eluting) balloon were required in case of total
occlusions and sub-occlusive lesions; however, adjuncts
to angioplasty, including atherectomy, cutting or scoring
balloons were not permitted. The subject was random-
ized to treatment with the IA-DEB or PTA only after
successful traversal of the TL and placement of the
guidewire into the distal true lumen. If all requirements
were not documented, the subject was considered a
screen failure.
After documentation of the above requirements, if the
subject was randomized to the investigational treatment,
the IA-DEB balloon of a diameter approximating a 1:1
ratio to the reference artery diameter was deployed and
inflated for a minimum of 1 min. If deemed necessary by
the operator, a post-dilatation of the TL was performed
using a standard short-length standard PTA balloon
intended to resolve persistent residual stenosis.
Provisional stenting was permitted according to the
following specific criteria:
a) Major dissection (grade C or above). However, in
order to limit stenting as much as possible,
prolonged standard PTA (3 min) with a non-drug-
eluting balloon was to be performed first.
b) Occlusive complication (e.g., recoil) that resulted in
severely decreased target vessel flow that did not
respond to repeated prolonged balloon inflation.
c) Persistent residual stenosis >50% (documented by
the worst of 2 orthogonal views after optimal PTA).
In the case of provisional stent implantation, a com-
mercially available bare metal stent could be used. As
Table 4 Trial assessment requirements
Baseline Procedure Discharge 30 days(24-45)
3 months
(84-105)(84-105)
6 months
(174-195)
1 year
(335-395)
2 years
(700-790)
3 years
(1065-1125)
4 years
(1430-1490)
5 years
(1795-1855) Unsched
Demography
X
Medical History
Physical Exam
X X X X X X X
Concomitant Meds
Anticoagulant/antiplatelet therapy X1 X2 X X
Informed Consent X
Incl/Excl Evaluation X X
Routine Lab testing (see Table 2) X3 X X X X X X
Ankle pressure, toe pressure, TcPO2, PVR
(at least 1 required) and brachial pressure
X3 X X X X X X
Wound assessment7 and Wound Care X X8 X X X X X
Rutherford Staging X X X X X X
EQ5D X3 X X X X
WIQ X X X X
Angiography X3 X X4 X5
Hospital FU Visits X X X X
Telephone FU X X X X
Adverse Event Assessment X X X X6 X X X X6 X6 X6 X
1Aspirin (100 mg) at least 4 days prior to the index intervention, alternatively at least 500 mg loading dose prior to or within 2 hours post procedure; Clopidogrel 75 mg daily at least 4 days prior to the index
intervention, alternatively at least 300 mg loading dose prior to or within 2 hours post procedure (or ticlopidine, if required); the use of bivalirudin (Angiox™) was allowed as an alternative to heparin.
2Following the PTA procedure, subjects were to be prescribed daily acetyl-salicylic acid (ASA) (100 mg) indefinitely and daily clopidogrel (75 mg) (or ticlopidine, if required) for at least 1 month following the procedure.
Prolonged antiplatelet therapy could be given at the discretion of the physician and should be considered after placement of stents.
3Within 6 weeks of procedure.
4For Angio Sub-group subjects only.
5If subject undergoes an unscheduled angiogram; a copy of the angiogram must be forwarded to the Angiographic Core Lab for adjudication.
6Only death and amputations.
7Wound assessment performed via the SilhouetteMobile.
8Only Wound Care.
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stents will be tracked in their respective assigned ran-
domized trial arms. A completion digital subtraction
angiogram in two oblique views of the TL and pedal
run-off was required.
Follow-up
Clinical follow-up will proceed as noted in Table 4. All
subjects will be followed for 5 years.
Data collection
Data will be collected via e-CRF during treatment at all
investigational centers and will be completed prospect-
ively during the hospital admission and follow-up.
Study device
IA-DEB manufactured by Medtronic (Santa Rosa, CA,
USA) features a 0.014” guidewire-compatible, over-the-
wire drug-eluting balloon that uses paclitaxel as the
therapeutic agent and urea as excipient. The characteris-
tics and mode of action of the IN.PACT drug-eluting
balloon have been described elsewhere [17,34,35].
Discussion
While the body of clinical experience involving the treat-
ment of CLI continues to evolve rapidly, our knowledge
and understanding of the many factors that impact treat-
ment outcomes of this heterogeneous and complex disease
state remain incomplete. Nevertheless, there have been im-
portant recent contributions to our appreciation of factors
affecting clinical outcomes, including the concept of
angiosome-directed revascularization and recognition of
the importance of restoring patency of the pedal run-off
vessels. New technology has also provided a potential im-
provement over current modalities of therapy. A substantial
treatment effect of the IA-DEB technology in improving
infrapopliteal vessel patency and reducing re-intervention
rates when compared to standard PTA has been reported
at 3-, 6-, and 12-month time points by single-center regis-
tries [10] and randomized trials [18,19].
The reduction in re-intervention rates in this challenging
CLI population is an undisputable hallmark of successful
IA-DEB use; however, the important “patient-centric” out-
comes of limb salvage, pain relief, mobility restoration, and
improvement in quality of life remain equally important
goals and endpoints in both clinical practice and research.
Unfortunately, these fundamental “patient-centric” end-
points and essential post-treatment care and follow-up are
infrequently pre-specified and/or are incompletely moni-
tored and reported in CLI trials. Nevertheless, the three IA-
DEB studies cited above reinforce the nature of the
challenges in establishing a clear correlation between im-
proved vessel patency and “patient-centric” outcomes.
They also emphasize that successful CLI care goes beyondpromoting durable vessel patency and is but one essential
aspect of a multidisciplinary team approach, an approach
that is representative of the IN.PACT DEEP trial design.
Therefore, as our clinical experience in the multifaceted
care and treatment of CLI patients evolves, the IN.PACT
DEEP stands as a unique milestone robust trial, which will
contribute to our fundamental understanding of the role of
durable vessel patency and its influence on “patient-centric”
outcomes targeting the full spectrum of Rutherford class 4-
5-6 critical limb ischemia and the identification of clinical
and anatomical profiles that will derive the optimal benefit
from DEB therapy.
Trial status
In.PACT DEEP completed subject enrollment/rando-
mization in July 2012, and the final enrolled subjects
returned for clinical follow-up in August 2013. Public pres-
entation of the trial co-primary and secondary endpoints is
expected in 2014.
Conclusion
The IN.PACT DEEP represents the first completed, largest,
prospective, multicenter, randomized, controlled compari-
son of plain old balloon angioplasty to drug-eluting balloon
angioplasty in infrapopliteal arteries of patients with CLI.
The trial design is rigorous and provides unbiased assess-
ment of outcomes through independent angiographic and
wound-healing core labs and clinical event committee adju-
dication. IN.PACT DEEP tests the hypothesis that the IN.
PACT Amphirion paclitaxel drug-eluting balloon provides
superior 1-year vessel patency, assessed by late lumen loss
(LLL), and whether any potential improvement in vessel pa-
tency is associated with a significant reduction in clinically
driven target lesion revascularization through 1 year. Clin-
ical follow-up is planned through 5 years and will continue
to yield important information regarding the long-term im-
pact of these two interventional strategies and set a new
standard for clinical evidence that will assist physicians and
caregivers with important direction in the care of this com-
plex and challenging patient cohort.
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